Dossier overview
4
research areas
3
references
3
handling notes
01
Mechanism of action
Retatrutide activates GIP, GLP-1, and glucagon . The combined agonism is associated with the glucose-control and appetite-reduction effects of incretin agents, plus the energy-expenditure effects ascribed to glucagon receptor activation in metabolic research.
02
Research applications
- Obesity clinical research (Phase II + Phase III)
- Type 2 diabetes clinical research
- Multi- incretin pharmacology
- Glucagon metabolic research
Evidence at a glance
What's behind this profile
3 citations · 2022–2023
- Human
- 3
Studies in human volunteers or patients (incl. early-phase trials).
Publication years
- 22
- 23
Counts are derived from the cited studies below. A study covering both in vivo and in vitro work is counted by its primary model. Sample size is reported in 2 of 3 citations. Findings remain model-specific and are not extrapolated to therapeutic use.
03
Study references
Each profile cites a minimum of two peer-reviewed sources, with model type and reported sample size where the source provides it. Findings are model-specific and must not be extrapolated to therapeutic use.
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
2022
Coskun T et al. · Cell Metabolism
- Model
- Preclinical pharmacology and Phase 1 single-ascending-dose study (mouse + human)
- Sample
- Not reported in abstract
Reported the discovery and Phase 1 first-in-human characterisation of LY3437943, with safety and weight-reduction signals in obese mice and healthy human volunteers.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
2023
Jastreboff AM et al. · New England Journal of Medicine
- Model
- Phase 2 double-blind RCT in adults with obesity or overweight with comorbidity
- Sample
- n=338
Retatrutide doses of 4–12 mg were associated with dose-dependent mean body weight reductions of 17.1% to 24.2% versus 2.1% with placebo over 48 weeks.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes
2023
Rosenstock J et al. · The Lancet
- Model
- Phase 2 double-blind RCT in adults with type 2 diabetes
- Sample
- n=281
Retatrutide doses of 4–12 mg were associated with dose-dependent HbA1c reductions up to 2.02% and body-weight reductions up to 16.94% over 36 weeks.
Evidence caveats
- Retatrutide is investigational. Phase III trials (TRIUMPH programme) are ongoing — no Phase III data are published at the time of writing.
- All published efficacy data are from Phase II trials with limited duration. Long-term safety and cardiovascular outcomes have not been established.
04
Storage and handling
Trial material follows the clinical trial protocol cold-chain. Research-grade material must be stored under controlled laboratory conditions per protocol.
- Investigational compound — all use is restricted to authorised clinical trials and research settings.
- Maintain full batch and supplier traceability.
- Trial product cold-chain follows the relevant clinical trial protocol.